登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Science，12月4日，Robust neutralizing antibodies to SARS-CoV-2 infection persist for months》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-12-22

  • Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
    View ORCID ProfileAnia Wajnberg1,*, View ORCID ProfileFatima Amanat2,3, Adolfo Firpo4, View ORCID ProfileDeena R. Altman5, Mark J. Bailey1, View ORCID ProfileMayce Mansour1,...

    Science  04 Dec 2020:
    Vol. 370, Issue 6521, pp. 1227-1230
    DOI: 10.1126/science.abd7728

    Abstract
    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection.

  • 原文来源：https://science.sciencemag.org/content/370/6521/1227
18浏览量
原文链接
相关报告

  • 《Science，1月12日，Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2021-02-08
    • Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape Paul-Albert Koenig1,2,*, View ORCID ProfileHrishikesh Das3,†, View ORCID ProfileHejun Liu4,†, Beate M. Kümmerer5,6, View ORCID ProfileFlorian N. Gohr2,‡, View ORCID ProfileLea-Mar... Science  12 Jan 2021: eabe6230 DOI: 10.1126/science.abe6230 Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to spread with devastating consequences. For passive immunization efforts, nanobodies have size and cost advantages over conventional antibodies. Here, we generated four neutralizing nanobodies that target the receptor-binding domain of the SARS-CoV-2 spike protein. We defined two distinct binding epitopes using x-ray crystallography and cryo-electron microscopy. Based on the structures, we engineered multivalent nanobodies with more than 100-fold improved neutralizing activity than monovalent nanobodies. Biparatopic nanobody fusions suppressed the emergence of escape mutants. Several nanobody constructs neutralized through receptor-binding competition, while other monovalent and biparatopic nanobodies triggered aberrant activation of the spike fusion machinery. These premature conformational changes in the spike protein forestalled productive fusion, and rendered the virions non-infectious.
    33浏览量
    原文链接

  • 《Cell，4月2日，Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-05
    • Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses Shibo Jiang Christopher Hillyer Lanying Du Open AccessPublished:April 02, 2020DOI:https://doi.org/10.1016/j.it.2020.03.007 Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs.
    118浏览量
    原文链接